Preclinical studies have observed reductions in Notch signaling after treatment with G9, a small-molecule USP9x inhibitor, together with remodeling of the tumor-associated immune environment and decreased tumor growth, with minimal toxicity34. This evidence concerns the gene USP9X and neoplasm.